MAPT and Alzheimer disease: Natural history studies have shown that plasma P‐tau has properties that may make it suitable as a pharmacodynamic marker, including longitudinal increases over a few years in both the preclinical and prodromal stages of AD, and longitudinal correlations with measures of cognition and brain structure (Mattsson‐Carlgren et al, 2020b).